FormBlends Launches Comprehensive GLP-1 and Peptide Intelligence Platform

New platform features 7,282 provider profiles and 100 clinical research reports to address information gap in fast-growing weight management drug category

Apr. 8, 2026 at 8:59am by Ben Kaplan

Got story updates? Submit your updates here. ›

A minimalist, glowing neon outline of a medical syringe or pill capsule against a dark background, conceptually representing the advanced technology of GLP-1 and peptide therapies.FormBlends' new platform aims to provide clarity and transparency around the rapidly evolving world of prescription weight management medications.San Francisco Today

FormBlends, a health technology platform focused on GLP-1 weight loss results and provider directory listings, has announced the completion of a major platform expansion that positions it as the most comprehensive consumer intelligence resource for prescription weight management medications in the United States. The platform now features 7,282 individually profiled provider listings, 100 physician-reviewed clinical research reports, 17 interactive health tools, and a clinical education library covering GLP-1 and peptide therapies.

Why it matters

The explosive growth of GLP-1 receptor agonist therapies has created an information gap, with the National Consumers League documenting a 1,200% increase in 'violative or problematic' GLP-1-related advertising between 2022 and 2024. FormBlends aims to close this gap by providing physician-reviewed, evidence-based clinical content to help patients make informed decisions about these treatments.

The details

FormBlends' new platform includes a National Provider Directory with 7,282 individually profiled weight management clinic listings, a Clinical Research Library with 100 physician-reviewed reports, 17 interactive health tools, and an Educational Article Library with comprehensive guides on GLP-1 receptor agonists, peptide therapy, and related topics. The platform's goal is to make published clinical data accessible to patients so they can have informed conversations with their physicians.

  • FormBlends announced the completion of its platform expansion on April 8, 2026.
  • Beginning July 1, 2026, Medicare will cover select GLP-1 receptor agonist medications for weight management at a $50 per month copay through the new 'Medicare GLP-1 Bridge' program.
  • The CMS BALANCE Model, launching January 2027 for Medicare Part D, is projected to further expand access to GLP-1 medications.

The players

FormBlends

A health technology platform focused on GLP-1 weight loss results and provider directory listings, building the definitive consumer resource for evidence-based medication information, provider transparency, and clinical education.

Got photos? Submit your photos here. ›

What they’re saying

“Patients are navigating an information environment where marketing is frequently disguised as medical advice. The gap between what consumers need to know and what they can reliably find online is widening every month. We built this platform to close that gap with physician-reviewed, evidence-based clinical content.”

— FormBlends spokesperson

“We are not building a company that happens to have health content. We are building the most trusted clinical resource on the internet for GLP-1 and peptide therapy information, backed by peer-reviewed research and transparent provider data.”

— FormBlends spokesperson

What’s next

Medicare coverage for GLP-1 medications will bring tens of millions of new patients into this category for the first time, increasing demand for reliable, physician-reviewed information that FormBlends aims to provide.

The takeaway

FormBlends is building the definitive consumer resource for evidence-based GLP-1 and peptide therapy information, addressing an information gap in the fast-growing weight management drug category and empowering patients to make informed decisions about these treatments.